{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-025835","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.566719+00:00","generated_at":"2026-05-18T06:26:56.132942+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%","bullets":["Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.","Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.","Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.","Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.","FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-025835","json":"https://secwatch.observer/filing/0001140361-25-025835.json","markdown":"https://secwatch.observer/filing/0001140361-25-025835.md","text":"https://secwatch.observer/filing/0001140361-25-025835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/0001140361-25-025835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/ef20051984_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T06:26:56.132942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}